Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 6;72(5):1541–1555. doi: 10.1002/hep.31160

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 2 — Assessment of ex vivo tetramer⁺ CD4⁺ T cells pre‐DAA and post‐DAA treatment, following vaccination and in SR volunteers. (A,B) FACS example plot of staining with tetramers 14 HCV‐NS4B_1806‐1818, 24 HCV‐NS3_1535‐1551 or pool of tetramers 17 HCV‐NS3_1582‐1597, tetramer 18 HCV‐NS3_1411‐1425, and tetramer 19 HCV‐NS3_1535‐1551 in 2 DAA patients pretherapy and posttherapy and in 2 SRs. Gating is on live CD3⁺ cells. Values indicate the percentage of CD4⁺ T cells binding the tetramer. (C) Percentage of tetramer⁺ CD4⁺ cells after ex vivo staining at the end of study of vaccinated healthy volunteers, DAA pretherapy and posttherapy, and in SR persons. Error bars represent the SEM. Only statistical differences are shown.